AlphaCentric Advisors LLC Raises Holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

AlphaCentric Advisors LLC lifted its holdings in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 20.0% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 30,000 shares of the company’s stock after buying an additional 5,000 shares during the period. Amphastar Pharmaceuticals comprises 1.1% of AlphaCentric Advisors LLC’s investment portfolio, making the stock its 29th biggest holding. AlphaCentric Advisors LLC owned approximately 0.06% of Amphastar Pharmaceuticals worth $1,456,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. GAMMA Investing LLC grew its holdings in shares of Amphastar Pharmaceuticals by 70.0% in the 3rd quarter. GAMMA Investing LLC now owns 663 shares of the company’s stock worth $32,000 after acquiring an additional 273 shares during the period. Innealta Capital LLC acquired a new stake in shares of Amphastar Pharmaceuticals in the 2nd quarter worth approximately $55,000. Blue Trust Inc. grew its holdings in Amphastar Pharmaceuticals by 23.9% during the 2nd quarter. Blue Trust Inc. now owns 1,604 shares of the company’s stock valued at $70,000 after buying an additional 309 shares during the last quarter. Asset Management One Co. Ltd. acquired a new stake in Amphastar Pharmaceuticals during the 3rd quarter valued at $78,000. Finally, Mirae Asset Global Investments Co. Ltd. grew its holdings in Amphastar Pharmaceuticals by 20.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,761 shares of the company’s stock valued at $85,000 after buying an additional 301 shares during the last quarter. 65.09% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on AMPH. Piper Sandler lowered their target price on Amphastar Pharmaceuticals from $71.00 to $66.00 and set an “overweight” rating on the stock in a report on Thursday, August 8th. Needham & Company LLC reiterated a “hold” rating on shares of Amphastar Pharmaceuticals in a report on Thursday, August 8th. Finally, StockNews.com cut Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday. Three analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $63.00.

Insider Buying and Selling

In related news, Director Richard K. Prins sold 17,101 shares of the stock in a transaction on Monday, August 12th. The stock was sold at an average price of $43.07, for a total value of $736,540.07. Following the transaction, the director now directly owns 33,971 shares of the company’s stock, valued at approximately $1,463,130.97. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Amphastar Pharmaceuticals news, Director Floyd F. Petersen sold 3,000 shares of the business’s stock in a transaction dated Thursday, September 5th. The stock was sold at an average price of $46.47, for a total transaction of $139,410.00. Following the transaction, the director now owns 75,409 shares in the company, valued at $3,504,256.23. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Richard K. Prins sold 17,101 shares of the business’s stock in a transaction dated Monday, August 12th. The stock was sold at an average price of $43.07, for a total value of $736,540.07. Following the transaction, the director now owns 33,971 shares in the company, valued at approximately $1,463,130.97. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 24,101 shares of company stock valued at $1,069,350. 27.10% of the stock is currently owned by company insiders.

Amphastar Pharmaceuticals Price Performance

AMPH stock opened at $50.59 on Tuesday. Amphastar Pharmaceuticals, Inc. has a 52-week low of $36.56 and a 52-week high of $65.92. The stock’s fifty day simple moving average is $48.34 and its 200-day simple moving average is $43.97. The company has a quick ratio of 2.63, a current ratio of 3.52 and a debt-to-equity ratio of 0.82. The stock has a market capitalization of $2.46 billion, a price-to-earnings ratio of 16.16, a price-to-earnings-growth ratio of 0.96 and a beta of 0.82.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its earnings results on Wednesday, August 7th. The company reported $0.85 earnings per share for the quarter, topping the consensus estimate of $0.75 by $0.10. The business had revenue of $182.39 million for the quarter, compared to analyst estimates of $171.29 million. Amphastar Pharmaceuticals had a return on equity of 29.79% and a net margin of 23.36%. Equities research analysts expect that Amphastar Pharmaceuticals, Inc. will post 3.7 EPS for the current year.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.